GalXC

View On IC.GC.CA

ADVERTISED

on 18 Dec 2024

Last Applicant/ Owned by

Dicerna Pharmaceuticals, Inc.

87 Cambridgepark DriveCambridge MA 02140

Serial Number

2136866 filed on 16^th Jul 2021

Correspondent Address

ROBIC AGENCE PI S.E.C./ ROBIC IP AGENCY LP

630, boul. René-Lévesque Ouest20e étageMontréal

QUÉBEC

H3B1S6

GalXC

Trademark usage description

biologic preparations for use in targeted pharmaceutical therapies for the treatment of rare autoimmune diseases, cancers, genetic disorders, chronic Read More

Vienna Information

26 . 3 . 4

Several triangles, juxtaposed, joined or intersectingPlusieurs triangles, juxtaposés, accolés ou se coupant

26 . 3 . 24

Triangles with dark surfaces or parts of surfacesTriangles avec surface ou partie de la surface foncée

25 . 7 . 1

Surfaces or backgrounds covered with repeated geometrical figures or designsSurfaces ou fonds couverts de figures ou de motifs géométriques répétés

25 . 7 . 8

Surfaces or backgrounds covered with other repeated geometrical figures or designsSurfaces ou fonds couverts d'autres figures ou motifs géométriques répétés

27 . 5 . 1

Letters presenting a special form of writingLettres présentant un graphisme spécial

27 . 5 . 4

Letters embellished or decorated with a drawing or composed of a collection of drawingsLettres enjolivées ou ornées d'un dessin ou composées par un assemblage de dessins

27 . 5 . 8

Letters linked to or containing a figurative element -- Note: Letters representing a human being or a part of the human body, an animal or a part of an animal's body, a plant, a heavenly body, a natural phenomenon or an object are classified in division 27.3.Lettres liées à un élément figuratif ou contenant un élément figuratif -- Note: Les lettres représentant un être humain ou une partie du corps humain, un animal ou une partie du corps d'un animal, un végétal, un corps céleste, un phénomène naturel ou un objet sont classées dans la division 27.3.

Classification Information

Class [005]
Biologic preparations for use in targeted pharmaceutical therapies for the treatment of rare autoimmune diseases, cancers, genetic disorders, chronic liver diseases, cardiovascular diseases and viral infections in the nature of herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS), COVID-19, pneumonia; biological preparations made from human blood cells for the treatment of rare autoimmune diseases, cancers, genetic disorders, chronic liver diseases, cardiovascular diseases and viral infections in the nature of herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS), COVID-19 and pneumonia, namely a biological compound in the form of a molecular complex that acts as a platform for the delivery of RNA-based drugs to biological cells; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies; oligonucleotide compounds for use in the targeted delivery of RNAi therapy; oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for a wide range of medical purposes.

Classification kind code

Class [040]
Custom manufacture of oligonucleotides.

Classification kind code

Class [042]
Research and development of pharmaceutical products; research and development of oligonucleotide drug delivery platforms for use in the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and viral infections.

Classification kind code

Mark Details

Serial Number

2136866

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 48 on 10^th Nov 2023	Agent Changed
Submitted for opposition 22 on 11^th Jan 2023	Search Recorded
Submitted for opposition 20 on 11^th Jan 2023	Examiner's First Report
Submitted for opposition 223 on 11^th Jan 2023	Total Provisional Refusal
Submitted for opposition 256 on 1^st Aug 2022	Notification of Possible Opposition Sent
Submitted for opposition 257 on 30^th Sept 2021	Designation Notification - Madrid Protocol
Submitted for opposition 31 on 29^th Sept 2021	Formalized
Submitted for opposition 1 on 29^th Sept 2021	Created
Submitted for opposition 228 on 16^th Jul 2021	International Registration
Submitted for opposition 30 on 16^th Jul 2021	Filed

GalXC

Classification Information

Classification kind code

Class [040]Custom manufacture of oligonucleotides.

Classification kind code

Class [042]Research and development of pharmaceutical products; research and development of oligonucleotide drug delivery platforms for use in the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and viral infections.

Classification kind code

Mark Details

Serial Number

Mark Type

Legal History

Class [040]
Custom manufacture of oligonucleotides.

Class [042]
Research and development of pharmaceutical products; research and development of oligonucleotide drug delivery platforms for use in the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and viral infections.